PREDICTING ANTI-LEUKEMIA ACTIVITY OF THE BCL-2-SELECTIVE INHIBITOR ABT-199 IN BCP-ALL BY FUNCTIONAL ASSESSMENT OF APOPTOSIS SIGNALING

被引：0
|
作者：
Seyfried, F. [1 ]
Demir, S. [1 ]
Hoerl, R. [1 ]
Ryan, J. [2 ]
Scheffold, A. [3 ]
Villalobos-Ortiz, M. [2 ]
Koehrer, S. [1 ]
Zinngrebe, J. [1 ]
Stilgenbauer, S. [3 ]
Letai, A. [2 ]
Debatin, K. -M. [1 ]
Meyer, L. H. [1 ]
机构：
[1] Ulm Univ, Med Ctr, Dept Pediat & Adolescent Med, Ulm, Germany
[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[3] Ulm Univ, Med Ctr, Dept Internal Med 3, Ulm, Germany
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P508
引用
收藏
页码：193 / 194
页数：2
相关论文
共 31 条
  • [1] Functional Mitochondrial Apoptosis Signaling Indicates Anti-Leukemia Activity of the BCL-2-Seletive Inhibitor ABT-199 in BCP-ALL
    Seyfried, F.
    Demir, S.
    Hoerl, R.
    Ryan, J.
    Scheffold, A.
    Villalobos-Ortiz, M.
    Koehrer, S.
    Zinngrebe, J.
    Stilgenbauer, S.
    Letai, A.
    Debatin, K. M.
    Meyer, L. H.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S115 - S115
  • [2] Anti-Leukemia Activity of the BCL-2 INHIBITOR ABT-199 in Pediatric BCP-ALL is Predicted by BCL-2/MCL-1 Expression Indicating Treatment Response
    Seyfried, F.
    Hoerl, R.
    Demir, S.
    Koehrer, S.
    Scheffold, A.
    Stilgenbauer, S.
    Debatin, K-M.
    Meyer, L. H.
    ANNALS OF HEMATOLOGY, 2017, 96 : S79 - S79
  • [3] BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia
    Pan, Rongqing
    Debose, LaKeisha
    Benito, Juliana M.
    Golfman, Leonard S.
    Zweidler-McKay, Patrick A.
    Han, Lina
    Harutyunyan, Karine G.
    Mu, Hong
    Ruvolo, Vivian R.
    Park, Eugene
    Muschen, Markus
    Leverson, Joel
    Borthakur, Gautam
    Kantarjian, Hagop M.
    Ruvolo, Peter P.
    Andreeff, Michael
    Konopleva, Marina
    BLOOD, 2013, 122 (21)
  • [4] Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
    Niu, X.
    Wang, G.
    Wang, Y.
    Caldwel, J. T.
    Edwards, H.
    Xie, C.
    Taub, J. W.
    Li, C.
    Lin, H.
    Ge, Y.
    LEUKEMIA, 2014, 28 (07) : 1557 - 1560
  • [5] Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199
    X Niu
    G Wang
    Y Wang
    J T Caldwell
    H Edwards
    C Xie
    J W Taub
    C Li
    H Lin
    Y Ge
    Leukemia, 2014, 28 : 1557 - 1560
  • [6] Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
    Zhao, Jianyun
    Niu, Xiaojia
    Li, Xinyu
    Edwards, Holly
    Wang, Guan
    Wang, Yue
    Taub, Jeffrey W.
    Lin, Hai
    Ge, Yubin
    ONCOTARGET, 2016, 7 (23) : 34785 - 34799
  • [7] Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
    Luedtke, Daniel A.
    Niu, Xiaojia
    Pan, Yihang
    Zhao, Jianyun
    Liu, Shuang
    Edwards, Holly
    Chen, Kang
    Lin, Hai
    Taub, Jeffrey W.
    Ge, Yubin
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2017, 2
  • [8] Inhibition of CHK1 Enhances Cell Death Induced By the Bcl-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells
    Zhao, Jianyun
    Niu, Xiaojia
    Edwards, Holly
    Wang, Yue
    Taub, Jeffrey W.
    Lin, Hai
    Ge, Yubin
    BLOOD, 2015, 126 (23)
  • [9] Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
    Daniel A Luedtke
    Xiaojia Niu
    Yihang Pan
    Jianyun Zhao
    Shuang Liu
    Holly Edwards
    Kang Chen
    Hai Lin
    Jeffrey W Taub
    Yubin Ge
    Signal Transduction and Targeted Therapy, 2
  • [10] Clinical proof of concept for the first-in-class BCL-2-selective inhibitor venetoclax (ABT-199/GDC-0199)
    Leverson, Joel D.
    CANCER RESEARCH, 2016, 76
1234